A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 48/00 (2006.01) A61K 9/127 (2006.01) A61K 31/70 (2006.01) A61K 47/28 (2006.01) C12N 15/11 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2256456
Pharmaceutical compositions for the treatment of pathologic conditions associated with the overexpression of ICAM-1 in a host. These pharmaceutical compositions comprise an effective amount of an ICAM-1 antisense molecule encapsulated in a lipid mixture which is typically a liposome or lipid particle. The lipid mixture will typically comprise at least two members selected from the group consisting of phospholipids, sterols and cationic lipids.
La présente invention se rapporte à des compositions pharmaceutiques destinées au traitement des troubles pathologiques associés à la sur-expression de la molécule-1 d'adhésion intercellulaire (ICAM-1) chez un hôte. Ces compositions pharmaceutiques comportent une quantité efficace d'une molécule anti-sens dirigée contre l'expression d'ICAM-1 et encapsulée dans un mélange lipidique qui est typiquement un liposome ou une particule lipidique. Ledit mélange lipidique doit comporter spécifiquement au moins deux éléments sélectionnés dans le groupe constitué par des phospholipides, des stérols et des lipides cationiques.
Bennett C. Frank
Hope Michael J.
Klimuk Sandra K.
Scherrer Peter
Semple Sean C.
Fetherstonhaugh & Co.
Isis Pharmaceuticals Inc.
The University Of British Columbia
LandOfFree
Enhanced efficacy of liposomal antisense delivery does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced efficacy of liposomal antisense delivery, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced efficacy of liposomal antisense delivery will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1835909